Canton Strategic Holdings CNTN
NASDAQ CNTN
$2.28 +0.03 (+1.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

Canton Strategic Holdings (CNTN) Net Income towards Common Stockholders (2021 - 2026)

Canton Strategic Holdings' (CNTN) quarterly Net Income towards Common Stockholders came in at -$47.3 million in Q1 2026, down 1762.66% YoY from $2.8 million in Q1 2025, and down 248.26% on a QoQ basis from -$13.6 million in Q4 2025.

Analysis

Canton Strategic Holdings (CNTN) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

Canton Strategic Holdings (CNTN) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$47.3 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 1762.66% year-over-year to -$47.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.9 million (down 421.27% YoY) and the FY2025 annual result came in at -$42.9 million, down 252.06% from the prior year.
  • Net Income towards Common Stockholders declined to -$47.3 million in Q1 2026, from -$13.6 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$197435.0 in Q4 2022 to a low of -$47.3 million in Q1 2026.
  • A 5-year average of -$5.6 million and a median of -$2.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 45.09% — and 2026, when it slumped 1762.66%.
  • Tracing CNTN's Net Income towards Common Stockholders over 5 years: stood at -$197435.0 in 2022, then plunged by 1152.96% to -$2.5 million in 2023, then slumped by 53.08% to -$3.8 million in 2024, then sank by 259.0% to -$13.6 million in 2025, then plunged by 248.26% to -$47.3 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$47.3 million (Q1 2026), -$13.6 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Canton Strategic Holdings 493.37 Mn 493.37 Mn - -19.25 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -19.25 Mn
Mar 31, 2026 -47.34 Mn
Dec 31, 2025 -13.59 Mn
Sep 30, 2025 -2.10 Mn
Jun 30, 2025 -1.86 Mn
Mar 31, 2025 -2.54 Mn
Dec 31, 2024 -3.82 Mn
Sep 30, 2024 -3.80 Mn
Jun 30, 2024 -2.33 Mn
Mar 31, 2024 -2.26 Mn
Dec 31, 2023 -2.47 Mn
Sep 30, 2023 -1.82 Mn
Jun 30, 2023 -2.34 Mn
Mar 31, 2023 -2.69 Mn
Dec 31, 2022 -1.76 Mn
Sep 30, 2022 -2.13 Mn
Jun 30, 2022 -1.64 Mn
Mar 31, 2022 -2.95 Mn
Dec 31, 2021 -359,870.00
Sep 30, 2021 -777,113.00